MSK Physician-Scientists Recognized with Top Honors by AACR, ASCO, and ASH Organizations

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and honors to our staff, given by the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the American Society of Hematology (ASH) organizations.

Read more

Andre Goy, M.D., Appointed Physician-in-Chief to Lead Cancer Care Across Hackensack Meridian Health Network

“Thanks to Andre Goy’s leadership, John Theurer Cancer Center has flourished to become one of the nation’s leading cancer care and research centers, and that expertise now extends throughout our entire network,” noted Robert C. Garrett, FACHE, CEO, Hackensack Meridian Health. “With Dr. Goy at the helm as physician-in-chief of the Hackensack Meridian Health Oncology Care Transformation Service, patients and physicians throughout the state will benefit from his acumen and vision.”

Read more

Bacteria in Cancer Cells May Help or Hinder Treatment

Weizmann Institute scientists show that bacteria live inside all cancer cells, from brain to breast to bone, and that each type of cancer has its own type of bacteria. Understanding this relationship could help predict treatment effectiveness or lead to ways of using the bacteria to boost treatments.

Read more

Study Shows Clinical Evidence of Anti-Tumor Activity in Patients with Metastatic Castration-Resistant Prostate Cancer

Results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC® protein degrader, demonstrates anti-tumor responses in patients with metastatic castration-resistant prostate cancer.

Read more

Study Shows Profound Benefit with Targeted Therapy for Patients with Early Stage NSCLC

According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.

Read more